$DVAX
DYNAVAX TECHNOLOGIES CORP

2014 Q1 Form 10-K Financial Statement

#000156459014000660 Filed on March 10, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q4 2013
Revenue $3.498M $2.847M $11.25M
YoY Change 67.77% 57.64% 15.82%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.230M $3.710M $26.87M
YoY Change -51.93% -60.06% -4.58%
% of Gross Profit
Research & Development $13.23M $12.13M $50.87M
YoY Change -6.59% -3.12% 3.51%
% of Gross Profit
Depreciation & Amortization $340.0K $340.0K $1.330M
YoY Change 6.25% 9.68% 9.92%
% of Gross Profit
Operating Expenses $13.23M $15.84M $50.87M
YoY Change -6.59% -27.37% 3.51%
Operating Profit -$13.97M -$66.49M
YoY Change -33.11% -1.64%
Interest Expense $70.00K $40.00K $120.0K
YoY Change 118.75% -108.0% -94.9%
% of Operating Profit
Other Income/Expense, Net $62.00K -$100.0K -$348.0K
YoY Change 342.86% 150.0% 18.77%
Pretax Income -$13.84M -$13.06M -$67.00M
YoY Change -33.56% -36.42% -5.35%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.84M -$13.06M -$66.72M
YoY Change -33.54% -36.45% -4.62%
Net Earnings / Revenue -395.65% -458.59% -593.01%
Basic Earnings Per Share
Diluted Earnings Per Share -$526.6K -$552.9K -$3.399M
COMMON SHARES
Basic Shares Outstanding 262.9M 262.6M
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 Q4 2013
SHORT-TERM ASSETS
Cash & Short-Term Investments $177.7M $189.4M $189.4M
YoY Change 68.6% 51.38% 51.4%
Cash & Equivalents $26.75M $23.12M $23.10M
Short-Term Investments $150.9M $166.3M $166.3M
Other Short-Term Assets $2.300M $1.400M $1.400M
YoY Change 91.67% -33.33% -33.33%
Inventory
Prepaid Expenses
Receivables $1.700M $1.627M $1.600M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $181.7M $192.4M $192.4M
YoY Change 68.03% 50.08% 50.08%
LONG-TERM ASSETS
Property, Plant & Equipment $8.600M $8.706M $8.700M
YoY Change 7.88% 9.3% 8.75%
Goodwill $2.579M
YoY Change 4.2%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $700.0K $297.0K $1.000M
YoY Change 49.57% -37.21% -9.09%
Total Long-Term Assets $11.90M $12.24M $12.20M
YoY Change 3.62% 5.87% 5.17%
TOTAL ASSETS
Total Short-Term Assets $181.7M $192.4M $192.4M
Total Long-Term Assets $11.90M $12.24M $12.20M
Total Assets $193.6M $204.6M $204.6M
YoY Change 61.84% 46.42% 46.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.900M $1.901M $1.900M
YoY Change 10.02% -12.23% -13.64%
Accrued Expenses $6.600M $5.764M $8.200M
YoY Change -19.18% -42.72% -18.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.00M $16.19M $16.20M
YoY Change -6.21% -14.84% -14.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.800M $963.0K $2.100M
YoY Change 511.92% 53.1% -64.41%
Total Long-Term Liabilities $3.800M $963.0K $2.100M
YoY Change 511.92% 53.1% -64.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.00M $16.19M $16.20M
Total Long-Term Liabilities $3.800M $963.0K $2.100M
Total Liabilities $19.70M $18.33M $18.30M
YoY Change -9.19% -26.47% -26.51%
SHAREHOLDERS EQUITY
Retained Earnings -$516.1M -$502.2M
YoY Change 13.09% 15.32%
Common Stock $263.0K $688.7M
YoY Change 43.72% 376213.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $173.9M $186.3M $186.3M
YoY Change
Total Liabilities & Shareholders Equity $193.6M $204.6M $204.6M
YoY Change 61.83% 46.42% 46.35%

Cashflow Statement

Concept 2014 Q1 2013 Q4 2013
OPERATING ACTIVITIES
Net Income -$13.84M -$13.06M -$66.72M
YoY Change -33.54% -36.45% -4.62%
Depreciation, Depletion And Amortization $340.0K $340.0K $1.330M
YoY Change 6.25% 9.68% 9.92%
Cash From Operating Activities -$11.18M -$11.84M -$58.67M
YoY Change -40.8% 55.99% 33.93%
INVESTING ACTIVITIES
Capital Expenditures $398.0K -$310.0K $1.629M
YoY Change -25.61% -74.17% -44.42%
Acquisitions
YoY Change
Other Investing Activities $15.13M -$102.3M -$49.72M
YoY Change -58.99% -1865.98% 35.26%
Cash From Investing Activities $14.73M -$102.6M -$51.35M
YoY Change -59.48% -2334.64% 29.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $80.86M
YoY Change 12.64%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K 125.3M 125.4M
YoY Change 366.67% -983.57% 112.39%
NET CHANGE
Cash From Operating Activities -11.18M -11.84M -58.67M
Cash From Investing Activities 14.73M -102.6M -51.35M
Cash From Financing Activities 70.00K 125.3M 125.4M
Net Change In Cash 3.620M 10.88M 15.38M
YoY Change -79.29% -163.33% -162.86%
FREE CASH FLOW
Cash From Operating Activities -$11.18M -$11.84M -$58.67M
Capital Expenditures $398.0K -$310.0K $1.629M
Free Cash Flow -$11.58M -$11.53M -$60.30M
YoY Change -40.38% 80.44% 29.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
262855958
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7599000
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7965000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-148000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28164000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25943000
CY2011 us-gaap Costs And Expenses
CostsAndExpenses
69191000
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
834000
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001029142
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Entity Registrant Name
EntityRegistrantName
DYNAVAX TECHNOLOGIES CORP
CY2013 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16192000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1173000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2052000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
128187000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1375000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
192378000
CY2013 dei Trading Symbol
TradingSymbol
DVAX
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
688390000
CY2012Q4 us-gaap Assets
Assets
139752000
CY2012Q4 us-gaap Goodwill
Goodwill
2475000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
297000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1901000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
473000
CY2013Q4 us-gaap Goodwill
Goodwill
2579000
CY2013Q4 us-gaap Assets
Assets
204622000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
662000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
652000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
550729000
CY2012 us-gaap Contracts Revenue
ContractsRevenue
4610000
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-69949000
CY2013 us-gaap Revenue From Grants
RevenueFromGrants
5138000
CY2013 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1184000
CY2012 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1165000
CY2013 us-gaap Revenues
Revenues
11251000
CY2012 us-gaap Revenues
Revenues
9714000
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17570000
CY2013 dvax Unoccupied Facility Expense
UnoccupiedFacilityExpense
926000
CY2011 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
299000
CY2012 us-gaap Interest Expense
InterestExpense
2351000
CY2013Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
166254000
CY2012Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
117531000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10063000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6125000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6785000
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5283000
CY2013 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
8469000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-75189000
CY2011 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48597000
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
52111000
CY2011 dvax Issuance Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Value
IssuanceOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsValue
10000
CY2011 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
132000
CY2011 dvax Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
91298000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5189000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
99880000
CY2012 dvax Issuance Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Value
IssuanceOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsValue
1955000
CY2012 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
307000
CY2012 dvax Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
71780000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10439000
CY2013 dvax Issuance Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Value
IssuanceOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsValue
112000
CY2013 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
224000
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
44209000
CY2013 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
CY2013 us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
CY2013 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
-143000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12340000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1327000
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1207000
CY2011 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1303000
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-18000
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-8000
CY2011 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-20000
CY2013 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-923000
CY2012 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1298000
CY2011 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1172000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23122000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1627000
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1005000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2166000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
186294000
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q2 dei Entity Public Float
EntityPublicFloat
105519624
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
170469000
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2011 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
14000
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
80999000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
629000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8706000
CY2013Q4 us-gaap Liabilities
Liabilities
18328000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
183000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-435491000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139752000
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-595000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-502211000
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
114826000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
204622000
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
263000
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-66720000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-69949000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-48597000
CY2012 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
366000
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
414000
CY2011 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-263000
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48860000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-293000
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
196275000
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-76000
CY2012 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
48000
CY2013 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
523000
CY2011 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-277000
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
447000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69535000
CY2011 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
132000
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
192044000
CY2012 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
206149000
CY2011 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
111205000
CY2013 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
142321000
CY2012 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
169387000
CY2011 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
77729000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2931000
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1142000
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34618000
CY2012 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
307000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
125401000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59042000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49146000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
262796000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50870000
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51322000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
262796000
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-348000
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19014000
CY2012Q4 us-gaap Liabilities
Liabilities
24926000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8166000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66273000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
963000
CY2013 dvax Supplemental Disposal Of Assets
SupplementalDisposalOfAssets
86000
CY2011 us-gaap Contracts Revenue
ContractsRevenue
17190000
CY2012 us-gaap Revenue From Grants
RevenueFromGrants
3939000
CY2011 us-gaap Revenue From Grants
RevenueFromGrants
3110000
CY2011 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1314000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
182792000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
182792000
CY2013 us-gaap Contracts Revenue
ContractsRevenue
4929000
CY2011 us-gaap Revenues
Revenues
21614000
CY2012 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2190000
CY2011 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1871000
CY2011 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
843000
CY2013 us-gaap Business Exit Costs1
BusinessExitCosts1
926000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
12340000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
10439000
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
5189000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
622000
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8522000
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8526000
CY2013 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-677000
CY2012 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
922000
CY2011 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-230000
CY2013 dvax Increase Decrease In Restricted Cash And Other Assets For Operating Activities
IncreaseDecreaseInRestrictedCashAndOtherAssetsForOperatingActivities
-176000
CY2012 dvax Increase Decrease In Restricted Cash And Other Assets For Operating Activities
IncreaseDecreaseInRestrictedCashAndOtherAssetsForOperatingActivities
116000
CY2011 dvax Increase Decrease In Restricted Cash And Other Assets For Operating Activities
IncreaseDecreaseInRestrictedCashAndOtherAssetsForOperatingActivities
290000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-657000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
126000
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-289000
CY2013 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2291000
CY2012 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1916000
CY2011 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2167000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4770000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1472000
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3512000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58673000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43809000
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47116000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1629000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51352000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39693000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
80856000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
71780000
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
91298000
CY2013 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
44209000
CY2013 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
CY2012 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
CY2011 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
112000
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1955000
CY2011 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000
CY2013 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
224000
CY2012 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
15000000
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
91440000
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
147000
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
118000
CY2011 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-218000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
15523000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-24342000
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9488000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31941000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22453000
CY2012 dvax Supplemental Disposal Of Assets
SupplementalDisposalOfAssets
169000
CY2011 dvax Supplemental Disposal Of Assets
SupplementalDisposalOfAssets
1181000
CY2013 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-76000
CY2012 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
48000
CY2011 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
14000
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;font-family:Times New Roman;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </font></p><p style="margin-bottom:0pt;margin-top:6pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires management to make informed </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ materially from these estimates.</font></p></div>
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;font-family:Times New Roman;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </font></p><p style="margin-bottom:0pt;margin-top:6pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">We operate in one</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> business segment, which is the discovery and development of biopharmaceutical products. We determine our segments based on the way we organize our business by making operating decisions and assessing performance. In fiscal years 2013, 2012 and 2011, 89%, 88% and 94% of our revenues were earned in the United States, respectively, and the remaining revenues were earned in Germany. As of December&#160;31, 2013 and 2012, 9% and 10%, respectively, of our long-lived assets were located in the United States and the remaining long-lived assets were located in Germany. </font></p><p style="margin-bottom:0pt;margin-top:12pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable. Our policy is to invest cash in institutional money market funds and marketable securities of U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">money market funds, U.S. government agency securities, U.S. treasury securities and municipal securities. We have not experienced any losses on our cash equivalents and marketable securities. </font></p><p style="margin-bottom:0pt;margin-top:12pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">Accounts receivable are recorded at invoice value. We review our exposure to accounts receivable, including the requirement</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for allowances based on management&#8217;s judgment. We have not historically experienced any significant losses. We do not currently require collateral for any of our accounts receivable. </font></p><p style="margin-bottom:0pt;margin-top:12pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">Our products will require approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our products will receive any of these required approvals. The denial or delay of such approvals would have a material adverse impact on our business. </font></p><p style="margin-bottom:0pt;margin-top:12pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">We have relied on a limited number of suppliers to produce oligonucleotides </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for clinical trials and a single contract manufacturer to produce our first generation TLR 9 agonist, 1018 for HEPLISAV-B. The loss of our current supplier would have a significant effect on our ability to produce HEPLISAV-B for commercialization and development of our other product candidates. To date, we have manufactured only small quantities of oligonucleotides and 1018 ourselves for development purposes. </font></p><p style="margin-bottom:0pt;margin-top:12pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishing appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of our stock price and the need to obtain additional financing.</font></p></div>
CY2013Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
189400000
CY2013 dvax Number Of Reporting Units
NumberOfReportingUnits
1
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2013 dvax Reclassification Adjustments From Accumulated Other Comprehensive Income
ReclassificationAdjustmentsFromAccumulatedOtherComprehensiveIncome
0
CY2013 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
189407000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
125085000
CY2013Q4 dvax Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
16000
CY2012Q4 dvax Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
46000
CY2013Q4 dvax Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
47000
CY2012Q4 dvax Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
1000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
189376000
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
125130000
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
93691000
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
72594000
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
166285000
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
93701000
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
72553000
CY2013Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
166254000
CY2013 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2012 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2011 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2013Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
8968000
CY2012Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
7574000
CY2013Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
1056000
CY2012Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
983000
CY2013Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
6048000
CY2012Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
600000
CY2012Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
5445000
CY2013Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
762000
CY2012Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
1047000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26023000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23611000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17317000
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15646000
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2013Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3639000
CY2012Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4538000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
338000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
396000
CY2013Q4 dvax Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
2403000
CY2012Q4 dvax Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
3207000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1786000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1922000
CY2006Q2 dvax Warrants Exercisable Period
WarrantsExercisablePeriod
P5Y
CY2006Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
7.32
CY2007Q2 us-gaap Other Commitment
OtherCommitment
15000000
CY2009Q4 dvax Issue Of Warrants To Purchase Shares Of Common Stock
IssueOfWarrantsToPurchaseSharesOfCommonStock
2000000
CY2009Q4 dvax Warrants Exercisable Period
WarrantsExercisablePeriod
P5Y
CY2009Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.94
CY2009Q4 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
13000000
CY2009Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2009Q4 us-gaap Subordinated Borrowing Due Date
SubordinatedBorrowingDueDate
2012-12-31
CY2009Q4 dvax Business Acquisition Contingent Consideration Percentage
BusinessAcquisitionContingentConsiderationPercentage
0.50
CY2009Q4 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
50000000
CY2013 us-gaap Fair Value Inputs Discount Rate
FairValueInputsDiscountRate
0.17
CY2010Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1076420
CY2010Q2 dvax Issue Of Warrants To Purchase Shares Of Common Stock
IssueOfWarrantsToPurchaseSharesOfCommonStock
7038210
CY2010Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.50
CY2010Q2 dvax Warrants Exercisable Period
WarrantsExercisablePeriod
P5Y
CY2010Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11100000
CY2010 us-gaap Malpractice Loss Contingency Discount Rate
MalpracticeLossContingencyDiscountRate
0.16
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2233000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2282000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2333000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2382000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1351000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
2499000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
13080000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1900000
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1700000
CY2011 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1700000
CY2013Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
600000
CY2013 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
4500000
CY2011 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
12000000
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
72934000
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28275000
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36830000
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2008Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2008Q4 us-gaap Dividend Payable Date To Be Paid Day Month And Year
DividendPayableDateToBePaidDayMonthAndYear
2008-11-17
CY2008Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2008Q4 us-gaap Share Price
SharePrice
6.00
CY2008Q4 dvax Rights Expiration Date
RightsExpirationDate
2008-11-17
CY2013Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
79570000
CY2013Q4 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
1.075
CY2012Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
17500000
CY2012Q2 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
4.25
CY2012Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
69600000
CY2011Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
27600000
CY2011Q4 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
3600000
CY2011Q4 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
2.50
CY2011Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
64500000
CY2010Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
26450000
CY2010Q4 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
3450000
CY2010Q4 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
1.70
CY2010Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
42000000
CY2010Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
41100000
CY2010Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3000000
CY2010Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
30293000
CY2010Q2 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
1.4525
CY2010Q2 dvax Number Of Shares Of Common Stock In Each Unit
NumberOfSharesOfCommonStockInEachUnit
1
CY2010Q2 dvax Number Of Warrants In Each Unit
NumberOfWarrantsInEachUnit
1
CY2010Q2 dvax Common Stock Issuable Upon Exercise Of Warrants Conversion Ratio
CommonStockIssuableUponExerciseOfWarrantsConversionRatio
0.5
CY2010Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.50
CY2010Q2 dvax Warrants Exercisable Period
WarrantsExercisablePeriod
P5Y
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10913873
CY2013Q4 dvax Warrant To Purchase Common Stock
WarrantToPurchaseCommonStock
12500000
CY2013Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.96
CY2013Q4 dvax Number Of Warrants Exercised During Period
NumberOfWarrantsExercisedDuringPeriod
250000
CY2012Q4 dvax Number Of Warrants Exercised During Period
NumberOfWarrantsExercisedDuringPeriod
13000000
CY2013Q4 dvax Number Of Share Based Compensation Plans
NumberOfShareBasedCompensationPlans
3
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13806000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
5614000
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
131000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15765000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
15765000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10628000
CY2012Q4 dvax Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Nonvested Weighted Average Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedWeightedAveragePrice
3.38
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.69
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.43
CY2013Q4 dvax Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Nonvested Weighted Average Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedWeightedAveragePrice
3.17
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
3.17
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.36
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y3M4D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y3M4D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y7M10D
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1427000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1427000
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1289000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2700000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
12100000
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
9600000
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2800000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2013 dvax Share Based Compensation Arrangement By Share Based Payment Award Options And Rsu Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsuOutstandingNumber
2047466
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4900000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1500000
CY2013 us-gaap Defined Contribution Plan Number Of Employees Covered
DefinedContributionPlanNumberOfEmployeesCovered
5
CY2012 us-gaap Defined Contribution Plan Number Of Employees Covered
DefinedContributionPlanNumberOfEmployeesCovered
1
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3800000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-67004000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-70792000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-49990000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
284000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
843000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1393000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-66720000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-69949000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-48597000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-22678000
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-23650000
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-16523000
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-178000
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-89000
CY2011 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2586000
CY2013 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
2515000
CY2011 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1394000
CY2013 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
3072000
CY2012 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
1002000
CY2011 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
595000
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
22354000
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
21966000
CY2011 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
18099000
CY2011 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-34000
CY2011 dvax Income Tax Reconciliation Change In Fair Value Measurement
IncomeTaxReconciliationChangeInFairValueMeasurement
286000
CY2011 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
509000
CY2011 us-gaap Income Tax Reconciliation Deductions Dividends
IncomeTaxReconciliationDeductionsDividends
273000
CY2013 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
CY2012 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
CY2011 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-55000
CY2012 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
771000
CY2011 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
775000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
147655000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
127529000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
21336000
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
18163000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
9501000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
8529000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
10662000
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12757000
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2486000
CY2012Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2180000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1222000
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1221000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
192862000
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
170379000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
192733000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
170232000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
129000
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
147000
CY2013Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
162000
CY2012Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
86000
CY2013Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
-33000
CY2012Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
61000
CY2013Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
129000
CY2012Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
147000
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
22500000
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
22000000
CY2011 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
18100000
CY2013Q4 us-gaap Deferred Taxes Business Combination Valuation Allowance Allocated To Contributed Capital
DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital
300000
CY2013Q1 us-gaap Revenues
Revenues
2085000
CY2013Q2 us-gaap Revenues
Revenues
3392000
CY2013Q3 us-gaap Revenues
Revenues
2927000
CY2013Q4 us-gaap Revenues
Revenues
2847000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-20825000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-17164000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-15675000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-13056000
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20825000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17164000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15675000
CY2013Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21525000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
182847000
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
182913000
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
183022000
CY2013Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
235879000
CY2012Q1 us-gaap Revenues
Revenues
2350000
CY2012Q2 us-gaap Revenues
Revenues
2684000
CY2012Q3 us-gaap Revenues
Revenues
2874000
CY2012Q4 us-gaap Revenues
Revenues
1806000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-16505000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-15110000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-17791000
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-20543000
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16505000
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15110000
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17791000
CY2012Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20543000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
155431000
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
167697000
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
177870000
CY2012Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
180685000

Files In Submission

Name View Source Status
0001564590-14-000660-index-headers.html Edgar Link pending
0001564590-14-000660-index.html Edgar Link pending
0001564590-14-000660.txt Edgar Link pending
0001564590-14-000660-xbrl.zip Edgar Link pending
dvax-10k_20131231.htm Edgar Link pending
dvax-20131231.xml Edgar Link completed
dvax-20131231.xsd Edgar Link pending
dvax-20131231_cal.xml Edgar Link unprocessable
dvax-20131231_def.xml Edgar Link unprocessable
dvax-20131231_lab.xml Edgar Link unprocessable
dvax-20131231_pre.xml Edgar Link unprocessable
dvax-ex10_201312311308.htm Edgar Link pending
dvax-ex10_201312311309.htm Edgar Link pending
dvax-ex10_20131231592.htm Edgar Link pending
dvax-ex10_20131231593.htm Edgar Link pending
dvax-ex10_20131231594.htm Edgar Link pending
dvax-ex10_20131231595.htm Edgar Link pending
dvax-ex10_20131231596.htm Edgar Link pending
dvax-ex12_20131231683.htm Edgar Link pending
dvax-ex21_201312316.htm Edgar Link pending
dvax-ex23_201312317.htm Edgar Link pending
dvax-ex31_20131231198.htm Edgar Link pending
dvax-ex31_20131231199.htm Edgar Link pending
dvax-ex32_2013123110.htm Edgar Link pending
dvax-ex32_2013123111.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g2014031017063104127.jpg Edgar Link pending
g2014031017063151028.jpg Edgar Link pending
g2014031017063188233.jpg Edgar Link pending
g2014031017063211734.jpg Edgar Link pending
g2014031017063222033.jpg Edgar Link pending
g2014031017063245434.jpg Edgar Link pending
g2014031017064504835.jpg Edgar Link pending
g2014031017064506336.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending